PEDIATRICS
Expert Insight View All

Pimecrolimus as a preferred option for mild-to-moderate atopic dermatitis - An updated recommendation for south and east asia

Eczema, also known as atopic dermatitis (AD), is a chronic, relapsing, inflammatory skin disease characterized by intense itch, recurrent eczematous lesions, and a fluctuating course.1,2 Statistics showed that up to 20% of children are affected by AD worldwide, while 15% of secondary school children in Hong Kong are reported to have the problem.3,4 In addition, evidence has suggested the prevalence of AD in Asia is on the rise.2 Although AD can be controlled through various proven strategies, optimizing AD management is still a challenge since certain situations, such as steroid phobia and poor patient compliance, could lead to treatment failure.4 In these regards, an algorithm for the topical AD treatment was developed and published in 2020 for use by the primary care physicians, pediatricians, and dermatologists in South and East Asia.2 In the interviews with Omnihealth Practice, Dr. Luk, Chi-Kong David and Professor Hon, Kam-Lun Ellis, authors of the practical recommendations, discussed the difficulties in managing mild-to-moderate AD, and shared their views on improving treatment outcomes in these AD patients.

28 Oct 2021
thumb

Dr. Luk, Chi-Kong David

Specialist in Paediatrics
President,
The Hong Kong Paediatric and Adolescent Dermatology Society

thumb

Professor Hon, Kam-Lun Ellis

Professor of Practice,
Department of Paediatrics,
CUHK Medical Centre,
The Chinese University of Hong Kong

News & Perspective View All
Infographics View All

Cardio-oncology monitoring in pediatric populations - Delphi consensus recommendations from an Australian and New Zealand expert group

28 Apr 2023